Powder: -20°C for 3 years | In solvent: -80°C for 1 year
1. Deoxyshikonin (Arnebin 7) may be a new drug candidate for wound healing and treatment of lymphatic diseases. 2. Deoxyshikonin enhances the ability of human dermal lymphatic microvascular endothelial cells (HMVEC-dLy) to undergo time-dependent in vitro cord formation. 3. Deoxyshikonin and dodecyl gallate show significantly synergic antimicrobial activity with penicillin in vivo and in vitro, and can effectively reduce nasopharyngeal and lung colonization caused by different penicillin-resistant pneumococcal serotypes.
説明 | 1. Deoxyshikonin (Arnebin 7) may be a new drug candidate for wound healing and treatment of lymphatic diseases. 2. Deoxyshikonin enhances the ability of human dermal lymphatic microvascular endothelial cells (HMVEC-dLy) to undergo time-dependent in vitro cord formation. 3. Deoxyshikonin and dodecyl gallate show significantly synergic antimicrobial activity with penicillin in vivo and in vitro, and can effectively reduce nasopharyngeal and lung colonization caused by different penicillin-resistant pneumococcal serotypes. |
植物由来 |
別名 | Arnebin 7 |
分子量 | 272.3 |
分子式 | C16H16O4 |
CAS No. | 43043-74-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 2.72 mg/mL (10 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Deoxyshikonin 43043-74-9 Chromatin/Epigenetic Metabolism Microbiology/Virology Others Antibacterial HIF/HIF Prolyl-Hydroxylase Inhibitor Bacterial Hypoxia-inducible factors inhibit HIFs HIF-PH Arnebin 7 inhibitor